The US Food and Drug Administration’s vaccine advisors continue to be skeptical of universal boosting of all US adults with mRNA COVID-19 vaccines, but Center for Biologics Evaluation and Research Director Peter Marks indicated he may want to move in that direction anyway.
FDA unexpectedly asked the Vaccines and Related Biological Products Advisory Committee to discuss whether available data support the use of a Pfizer Inc./BioNTech SE or Moderna, Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?